A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

被引：20

作者：

Jurczak, Wojciech ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Hess, Georg ^{[3
]}

Gaidano, Gianluca ^{[4
]}

Provencio, Mariano ^{[5
]}

Nagy, Zsolt ^{[6
]}

Robak, Tadeusz ^{[7
]}

Maddocks, Kami J. ^{[8
]}

Buske, Christian ^{[9
]}

Ambarkhane, Sumeet ^{[10
]}

Brugger, Wolfram ^{[10
]}

Dirnberger-Hertweck, Maren ^{[10
]}

Tillmanns, Sascha ^{[10
]}

Weirather, Johannes ^{[10
]}

Blum, Kristie ^{[11
]}

机构：

[1] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland

[2] Univ Bologna, Ist Ematol, Bologna, Italy

[3] Johannes Gutenberg Univ Mainz, Dept Hematol Med Oncol & Pneumol, Mainz, Germany

[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[5] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain

[6] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[7] Med Univ Lodz, Dept Hematol, Lodz, Poland

[8] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA

[9] Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[10] MorphoSys AG, Planegg, Germany

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124297

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4078

引用

页数：4

共 50 条

[21] Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Wen-ying Zhang
Yang Liu
Yao Wang
Chun-meng Wang
Qing-ming Yang
Hong-li Zhu
Wei-dong Han
Signal Transduction and Targeted Therapy, 2
[22] A phase II, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): Study PDX-015
Chang, J. E.
Rosen, P. J.
Diefenbach, C. S. Magid
Kacprowicz, H.
O'Connor, O.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Zhang, Wen-ying
Liu, Yang
Wang, Yao
Wang, Chun-meng
Yang, Qing-ming
Zhu, Hong-li
Han, Wei-dong
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
[24] Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study
Zinzani, Pier Luigi
Vose, Julie M.
Czuczman, Myron S.
Reeder, Craig
Haioun, Corinne
Polikoff, Jonathan
Tilly, Herve
Pietronigro, Dennis
Ervin-Haynes, Annette
Li, Ju
Witzig, Thomas E.
BLOOD, 2012, 120 (21)
[25] Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
Wang, Michael
Rule, Simon
Martin, Peter
Goy, Andre
Auer, Rebecca
Kahl, Brad S.
Jurczak, Wojciech
Advani, Ranjana
Romaguera, Jorge E.
Williams, Michael E.
Barrientos, Jacqueline C.
Chmielowska, Ewa
Radford, John
Stilgenbauer, Stephan
Dreylingls, Martin
Jedrzejczak, Wieslaw Wiktor
Johnson, Peter W.
Spurgeon, Stephen E.
Zhang, Liang
Baher, Linda
Cheng, Mei
Beaupre, Darrin M.
Blum, Kristie A.
BLOOD, 2014, 124 (21)
[26] An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma
Ogura, Michinori
Uchida, Toshiki
MacDonald, David A.
Hatake, Kiyohiko
Davies, Andrew
Sangha, Randeep
Crump, Michael
Thieblemont, Catherine
Ishibashi, Taro
Hua, Steven
Paccagnella, Luisa
Vandendries, Erik R.
Kobayashi, Yukio
Tobinai, Kensei
BLOOD, 2011, 118 (21) : 1587 - 1587
[27] PHASE I/II STUDY OF THE ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE SAR3419 ADMINISTERED WEEKLY TO PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL)
Coiffier, B.
Ribrag, V.
Dupuis, J.
Tilly, H.
Haioun, C.
Morschhauser, F.
Lamy, T.
Copie, C.
Brehar, O.
Houot, R.
Lambert, J.
Morariu-Zamfir, R.
ANNALS OF ONCOLOGY, 2011, 22 : 105 - 105
[28] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Earl, Christian Tyler
Wilding, Emily
Quinion, Carl
Lustberg, Mark
Benson, Don M., Jr.
Jones, Jeffrey A.
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2010, 116 (21) : 1148 - 1149
[29] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results
Cao, Xinxin
Jin, Jie
Cheng, Fu Cheng
Yi, Shuhua
Zhao, Weili
Sun, Zimin
Yang, Wei
Li, Dengju
Cui, Guohui
Hu, Jianda
Liu, Ting
Song, Yongping
Xu, Bing
Zhu, Zunmin
Xu, Wei
Zhang, Mingzhi
Li, Sichen
Wang, Weige
Zhao, Renbin
Zhou, Daobin
BLOOD, 2023, 142
[30] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Jones, Jeffrey A.
Benson, Don M., Jr.
Flynn, Joseph M.
Porcu, Pierluigi
Lustberg, Mark E.
Phelps, Mitchell
Poi, Ming
Chung, Diana
Quinion, Carl
Byrd, John C.
Wegener, William
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2011, 118 (21) : 1584 - 1584

← 1 2 3 4 5 →